Abstract
Objective: To analyze the literature on the relationship between the antidepressive agents most used by pregnant women and the increased incidence of congenital heart disease in the newborn (NB). Methods: Using the descriptors “Heart Defects, Congenital” and “Antidepressive Agents”, a search was performed in the databases MEDLINE/ PubMed, SciELO, LILACS and CAPES. As inclusion criteria, articles in English, Portuguese and Spanish were accepted, limited to the last 5 years (2015-2020) and that addressed the use of Selective Serotonin Reuptake Inhibitors (SSRIs) or Selective Serotonin and Noradrenaline Reuptake Inhibitors (SNRI) at any time during pregnancy. Articles without abstract or full text, duplicated, letters to the editor and those referring to heart diseases in adults and animals were excluded. Results: Initially, 29 articles were found, of these, 6 attended the criteria and discussed the influence of SNRI or SSRIs on cardiac malformations in newborns. Final considerations: Based on the retrieved articles, there isn't consensus on the association between the use of SSRIs or SNRI during pregnancy and the development of congenital heart diseases.